Suppr超能文献

米卡芬净抗真菌预防治疗在接受 HSCT 治疗的儿童中的应用:我们能否增加剂量、减少给药频率?一项药代动力学研究。

Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study.

机构信息

Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

出版信息

J Antimicrob Chemother. 2018 Jun 1;73(6):1651-1658. doi: 10.1093/jac/dky030.

Abstract

BACKGROUND

Micafungin has a distinct advantage for antifungal prophylaxis in HSCT owing to its better safety profile, specifically in terms of hepatic and renal toxicity. In children, prophylactic micafungin is given as either 1 mg/kg every day or 3 mg/kg every other day.

OBJECTIVES

We performed a prospective single-centre observational study that investigated the pharmacokinetics (PK) of a single 5 mg/kg dose of micafungin in young children undergoing HSCT, to ascertain the eventual feasibility of twice-weekly prophylactic administration.

METHODS

Nine children, ≤10 years of age undergoing HSCT, were enrolled and received a single intravenous dose of 5 mg/kg micafungin. Blood samples were obtained for PK analysis. Micafungin plasma concentration of >0.2 mg/L was chosen for target attainment (i.e. considered adequate prophylactic concentration). In addition, a population PK model was developed based on current and our previous PK study data. We also evaluated PK model-based simulation of PK profiles and target attainment using Monte Carlo simulation, for several dosing scenarios.

RESULTS

Mean clearance was 15.3 mL/h/kg (range 11.0-21.4 mL/h/kg) and the mean elimination half-life was 11.6 h (range 7.8-16.6 h). The mean concentration at 96 h was 0.11 mg/L (range 0.03-0.26 mg/L). Eleven percent (n = 1) of patients achieved target attainment at the end of 96 h. Simulation data showed that 1 mg/kg daily dosing and 3 mg/kg alternate-day dosing strategies achieved at least 99% and 81% target attainment, respectively, whereas a 5 mg/kg with 3 day-interval dosing strategy resulted in 64%, 72% and 84% target attainments in patients with body weights of 10, 20 and 30 kg, respectively.

CONCLUSIONS

Micafungin at 5 mg/kg dosing did not achieve target attainment at the end of 96 h for antifungal prophylaxis in children undergoing HSCT. Simulation data suggest that a dosing strategy of micafungin at 5 mg/kg every 72 h is more likely to achieve target attainment in children with a higher body weight in comparison with children with a lower body weight. A cautious approach is advisable when using a high, but less frequent, dosing strategy in very young children.

摘要

背景

米卡芬净在 HSCT 中的抗真菌预防具有明显优势,因为它具有更好的安全性,特别是在肝毒性和肾毒性方面。在儿童中,预防性米卡芬净的给药剂量为 1mg/kg 每天或 3mg/kg 每隔一天。

目的

我们进行了一项前瞻性单中心观察性研究,旨在研究接受 HSCT 的年轻儿童单次给予 5mg/kg 剂量的米卡芬净的药代动力学(PK),以确定每周两次预防性给药的可行性。

方法

9 名年龄≤10 岁接受 HSCT 的儿童接受了单次静脉注射 5mg/kg 米卡芬净。采集血样进行 PK 分析。选择米卡芬净血浆浓度>0.2mg/L 作为目标达到(即认为是足够的预防性浓度)。此外,根据当前和我们之前的 PK 研究数据,建立了一个群体 PK 模型。我们还使用蒙特卡罗模拟对几种给药方案进行了基于 PK 模型的 PK 曲线和目标达到的模拟。

结果

平均清除率为 15.3mL/h/kg(范围为 11.0-21.4mL/h/kg),平均消除半衰期为 11.6h(范围为 7.8-16.6h)。96 小时时的平均浓度为 0.11mg/L(范围为 0.03-0.26mg/L)。11%(n=1)的患者在 96 小时时达到目标浓度。模拟数据显示,1mg/kg 每日剂量和 3mg/kg 隔日剂量策略的目标达到率分别至少为 99%和 81%,而 5mg/kg 每 3 天给药策略在体重为 10、20 和 30kg 的患者中分别导致 64%、72%和 84%的目标达到率。

结论

对于接受 HSCT 的儿童,5mg/kg 剂量的米卡芬净在 96 小时时未达到预防真菌感染的目标浓度。模拟数据表明,与体重较低的儿童相比,5mg/kg 米卡芬净每 72 小时的给药策略更有可能在体重较高的儿童中达到目标浓度。在非常年幼的儿童中使用高但频率较低的给药策略时应谨慎。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验